Q-omics provides the consensus-scored TM7SF2 profile across patient tissues and cancer cell-line models. TM7SF2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, TM7SF2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TM7SF2 RNA expression shows 16,628 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LGG, HNSC, and TGCT as cancer lineages where TM7SF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TM7SF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TM7SF2 survival associations across molecular data types. TM7SF2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TM7SF2 RNA expression–survival associations across cancer types. High TM7SF2 expression shows unfavorable associations in SKCM, MESO and UCEC, but favorable associations in LGG, KIRC and KIRP. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for TM7SF2 RNA expression.
This table summarizes TM7SF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TM7SF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TM7SF2 shows lower tumor expression in HNSC and KIRC and higher tumor expression in COAD, BLCA, THCA and UCEC. The HNSC box plot shows higher TM7SF2 RNA expression in normal versus tumor tissue (log2 FC = −2.626, t-test p < 0.001).
This table shows molecular features associated with TM7SF2 in patient tissues and cancer cell lines. In patient samples, TM7SF2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TM7SF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
